More on BMY
Data
Financials
News
|
Bristol-Myers Squibb Co. (NY:BMY)
Delayed: 46.59
-0.26 (0.55%)
|
Trade Now! |
|
||||
|---|---|---|---|---|---|---|
| Previous Close | $46.85 | 52 Week High | $49.57 | |||
| Open | $46.60 | 52 Week Low | $30.64 | |||
| Day High | $46.79 | P/E | 53.55 | |||
| Day Low | $46.18 | EPS | $0.87 | |||
| Volume | 1,368,181 | |||||
- Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4
- AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza® (saxagliptin)
- Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based Careers
- Supreme Court Ruling Creates Uncertainly for Drug Makers (ACT) (MYL) (MRK)
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
- Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previous
- AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®
- Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
- Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia® SC (abatacept) in China
- Form 4 BRISTOL MYERS SQUIBB CO For: Jun 10 Filed by: von Autenried Paul
Entities mentioned with BMY
- Earnings | View Related Stories »
- Citi | View Related Stories »
- Bank of America | View Related Stories »
- Jefferies & Co | View Related Stories »
- Morgan Stanley | View Related Stories »
- Dividend | View Related Stories »
- Carl Icahn | View Related Stories »
- UBS | View Related Stories »
- Show More...
